Vice President Bioanalytical Services Celerion Lincoln, Nebraska
Whilst peptide drugs have increased in the portfolios of pharmaceutical companies in recent years, peptides as a modality have been used in treating human disease for over a century with insulin being the most famous example. However, advances in peptide drug design, recombinant technology and structural modification have allowed for more sophisticated peptides to be developed and investigated for a range of disease targets. So, whilst these modalities are not new in the purest sense, they present specific challenges for bioanalytical assessment. The presentation will cover considerations for developing and implementing a bioanalytical strategy for modern day peptide modalities.
